U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C25H28N6O
Molecular Weight 428.5304
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IRBESARTAN

SMILES

CCCCC1=NC2(CCCC2)C(=O)N1Cc3ccc(cc3)-c4ccccc4-c5n[nH]nn5

InChI

InChIKey=YOSHYTLCDANDAN-UHFFFAOYSA-N
InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)

HIDE SMILES / InChI
Irbesartan is an angiotensin receptor blocker (ARB) used mainly for the treatment of hypertension. It was developed by Sanofi Research (now part of Sanofi-Aventis). It is marketed under the trade names Aprovel, Karvea, and Avapro. AVAPRO is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria. Irbesartan is a specific competitive antagonist of AT1 receptors with a much greater affinity (more than 8500-fold) for the AT1 receptor than for the AT2 receptor and no agonist activity.

CNS Activity

Curator's Comment:: Studies in animals indicate that radiolabeled irbesartan weakly crosses the blood-brain barrier and placenta.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
AVAPRO

Approved Use

AVAPRO is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) • Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria

Launch Date

8.7557761E11
Primary
AVAPRO

Approved Use

AVAPRO is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) • Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria

Launch Date

8.7557761E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.3 μg/mL
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.9 μg/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
4.4 μg/mL
600 mg 1 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
4.9 μg/mL
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
5.6 μg/mL
900 mg 1 times / day multiple, oral
dose: 900 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
5.3 μg/mL
900 mg single, oral
dose: 900 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.04 μg/mL
150 mg 1 times / day multiple, oral
dose: 150 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1.9 μg/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
19.8 μg × h/mL
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
20 μg × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
31.9 μg × h/mL
600 mg 1 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
32.6 μg × h/mL
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
34.2 μg × h/mL
900 mg 1 times / day multiple, oral
dose: 900 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
44.8 μg × h/mL
900 mg single, oral
dose: 900 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
9.3 μg × h/mL
150 mg 1 times / day multiple, oral
dose: 150 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
9.7 μg × h/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11 h
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
14 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
15 h
600 mg 1 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
14 h
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
14 h
900 mg 1 times / day multiple, oral
dose: 900 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
17 h
900 mg single, oral
dose: 900 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
11 h
150 mg 1 times / day multiple, oral
dose: 150 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
16 h
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
unknown, unknown
IRBESARTAN serum
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
900 mg 1 times / day multiple, oral
Highest studied dose
Dose: 900 mg, 1 times / day
Route: oral
Route: multiple
Dose: 900 mg, 1 times / day
Sources: Page: p.247, p.250
healthy, 20-45
n = 9
Health Status: healthy
Age Group: 20-45
Sex: M+F
Population Size: 9
Sources: Page: p.247, p.250
Sources: Page: p.247, p.250
300 mg 1 times / day multiple, oral (max)
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hypertension|diabetic nephropathy
Sources: Page: p.1
Disc. AE: Disorder fetal...
AEs leading to
discontinuation/dose reduction:
Disorder fetal
Sources: Page: p.1
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Diabetic nephropathy
Sources: Page: p.6
Disc. AE: Hyperkalemia...
AEs leading to
discontinuation/dose reduction:
Hyperkalemia (2.1%)
Sources: Page: p.6
AEs

AEs

AESignificanceDosePopulation
Disorder fetal Disc. AE
300 mg 1 times / day multiple, oral (max)
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hypertension|diabetic nephropathy
Sources: Page: p.1
Hyperkalemia 2.1%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Diabetic nephropathy
Sources: Page: p.6
Overview

OverviewOther

Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
yes (co-administration study)
Comment: in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible
Page: 12.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Drug interactions with irbesartan.
2001
Hypertension and diabetes: the scope of the problem.
2001
Pharmacological differences among angiotensin II receptor antagonists.
2001
Perindopril/indapamide 2/0.625 mg/day: a review of its place in the management of hypertension.
2001
Vasoconstrictive drugs increase carbonic anhydrase I in vascular smooth muscle while vasodilating drugs reduce the activity of this isozyme by a direct mechanism of action.
2001
Angiotensin II AT(1) receptor antagonists and platelet activation.
2001
Effects of loop diuretics on angiotensin II-stimulated vascular smooth muscle cell growth.
2001
Drug interaction: omeprazole and phenprocoumon.
2001
Differential effects of enalapril and irbesartan in experimental papillary necrosis.
2001
Drug-induced cholestasis.
2001 Apr
Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications.
2001 Apr
Inhibition of the acute effects of angiotensin II by the receptor antagonist irbesartan in normotensive men.
2001 Apr
Renal safety of combined cyclooxygenase 2 (COX-2) inhibitor and angiotensin II receptor blocker administration in mild volume depletion.
2001 Apr 7
Acute oliguric renal failure associated with angiotensin II receptor antagonists.
2001 Aug
Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension.
2001 Aug
Irbesartan slows the development of diabetic nephropathy by up to 70% in hypertensive diabetic patients.
2001 Aug-Sep
Irbesartan prevents the progression of kidney disease or death in patients with type 2 diabetes and high blood pressure.
2001 Aug-Sep
The protective effect of blocking angiotensin in both type I and type II diabetics with nephropathy.
2001 Dec
AT(2) receptor-mediated vasodilation in the heart: effect of myocardial infarction.
2001 Dec
Left ventricular hypertrophy and angiotensin II antagonists.
2001 Feb
A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists.
2001 Feb 1
Angiotensin II type 1 receptor blockers.
2001 Feb 13
Endothelial dysfunction and oxidative stress during estrogen deficiency in spontaneously hypertensive rats.
2001 Jan 23
Angiotensin receptor blockers -- finally the evidence is coming in: IDNT and RENAAL.
2001 Jul
Insurmountable AT(1) receptor antagonism: the need for different antagonist binding states of the receptor.
2001 Jul
The pharmacokinetics of irbesartan in hypertensive children and adolescents.
2001 Jul
Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery.
2001 Jul
New stuff about the diabetic kidney.
2001 Jul-Aug
Synthesis and study of a cyclic angiotensin II antagonist analogue reveals the role of pi*--pi* interactions in the C-terminal aromatic residue for agonist activity and its structure resemblance with AT(1) non-peptide antagonists.
2001 Jun
Regression of left ventricular hypertrophy in human hypertension with irbesartan.
2001 Jun
Efficacy of an angiotensin II receptor antagonist in managing hyperaldosteronism.
2001 Jun
Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats.
2001 Jun
[Angiotensin II receptor antagonists: different or equivalent?].
2001 Jun 16-23
Angiotensin II subtype 1 receptor blockers and renal function.
2001 Jun 25
Apoptosis and changes in contractile protein pattern in the skeletal muscle in heart failure.
2001 Mar
The angiotensin II AT1 receptor antagonist irbesartan prevents thromboxane A2-induced vasoconstriction in the rat hind-limb vascular bed in vivo.
2001 Mar
Differential activation of extracellular signal-regulated protein kinase 1/2 and p38 mitogen activated-protein kinase by AT1 receptors in vascular smooth muscle cells from Wistar-Kyoto rats and spontaneously hypertensive rats.
2001 Mar
Inhibition of angiotensin II-induced facilitation of sympathetic neurotransmission in the pithed rat: a comparison between losartan, irbesartan, telmisartan, and captopril.
2001 Mar
Prevention of hypertension by irbesartan in Dahl S rats relates to central angiotensin II type 1 receptor blockade.
2001 Mar
[Milestone studies provide evidence: sartans have a nephroprotective effect. Evidence is clear].
2001 May 31
Drug companies should not have the final say in the design of clinical trials.
2001 Nov
[Clinical study of the month. Nephroprotective role of angiotensin II receptor antagonists in type 2 diabetes: results of the IDNT and RENAAL trials].
2001 Oct
pK(a) determination of angiotensin II receptor antagonists (ARA II) by spectrofluorimetry.
2001 Oct
Vasoconstrictor effect of the angiotensin-converting enzyme-resistant, chymase-specific substrate [Pro(11)(D)-Ala(12)] angiotensin I in human dorsal hand veins: in vivo demonstration of non-ace production of angiotensin II in humans.
2001 Oct 9
Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis.
2001 Sep
Differentiation in the angiotensin II receptor 1 blocker class on autonomic function.
2001 Sep
Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice.
2001 Sep
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
2001 Sep 20
Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.
2001 Sep-Oct
Vasoconstriction is determined by interstitial rather than circulating angiotensin II.
2002 Jan
Patents

Sample Use Guides

Usual Adult Dose for Hypertension Initial dose: 150 mg orally once a day Maximum dose: 300 mg orally once a day Usual Adult Dose for Diabetic Nephropathy Target maintenance dose: 300 mg orally once a day Use: Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (greater than 300 mg/day) in patients with type 2 diabetes and hypertension.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment:: Contraction responses to increasing concentrations of Ang I (1 nM-1 uM) were evaluated in organ baths in the presence of captopril (10 uM-1 mM) with or without a chymase inhibitor (1 uM soybean trypsin inhibitor), or irbesartan (0.1 nM-uM), in internal mammary arteries from 25 patients undergoing coronary bypass surgery.
0.1 uM irbesartan completely blocked the maximum response to Ang I (from 45.8 +/- 6.7% to 1.9 +/- 1.9%, p < 0.001)
Name Type Language
IRBESARTAN
EMA EPAR   EP   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
IRBESARTAN [EP]
Common Name English
1,3-DIAZASPIRO(4.4)NON-1-EN-4-ONE, 2-BUTYL-3-((2'-(1H-TETRAZOL-5-YL)(1,1'-BIPHENYL)-4-YL)METHYL)-
Systematic Name English
IBERSARTAN/HYDROCHLOROTHIAZIDE TEVA COMPONENT IBERSARTAN
Brand Name English
AVALIDE COMPONENT IRBESARTAN
Common Name English
IRBESARTAN [USP MONOGRAPH]
Common Name English
IRBESARTAN COMPONENT OF KARVEZIDE
Brand Name English
IRBESARTAN [INN]
Common Name English
IRBESARTAN [MI]
Common Name English
IBERSARTAN/HYDROCHLOROTHIAZIDE ZENTIVA COMPONENT IBERSARTAN
Brand Name English
IRBESARTAN ZENTIVA
Brand Name English
IRBESARTAN [USP-RS]
Common Name English
IBERSARTAN/HYDROCHLOROTHIAZIDE COMPONENT IBERSARTAN
Brand Name English
SARBEVEL
Brand Name English
IRBESARTAN [VANDF]
Common Name English
IRBESARTAN TEVA
Brand Name English
IRBESARTAN [EMA EPAR]
Common Name English
IRBESARTAN [USAN]
Common Name English
IRBESARTAN COMPONENT OF IFIRMACOMBI
Brand Name English
COAPROVEL COMPONENT IRBESARTAN
Brand Name English
IRBESARTAN BMS
Brand Name English
IRBESARTAN [WHO-DD]
Common Name English
BMS-186295
Code English
IRBESARTAN [USP]
Common Name English
IRBESARTAN [JAN]
Common Name English
IRBESARTAN [EP MONOGRAPH]
Common Name English
IRBESARTAN COMPONENT OF AVALIDE
Common Name English
IBERSARTAN COMPONENT OF IBERSARTAN/HYDROCHLOROTHIAZIDE TEVA
Brand Name English
IFIRMACOMBI COMPONENT IRBESARTAN
Brand Name English
SR 47436
Code English
IRBESARTAN COMPONENT OF COAPROVEL
Brand Name English
SR-47436
Code English
IRBESARTAN [ORANGE BOOK]
Common Name English
AVAPRO
Brand Name English
2-BUTYL-3-(P-(O-1H-TETRAZOL-5-YLPHENYL)BENZYL)-1,3-DIAZASPIRO(4.4)NON-1-EN-4-ONE
Common Name English
NSC-758696
Code English
IRBESARTAN [MART.]
Common Name English
KARVEA
Brand Name English
IBERSARTAN COMPONENT OF IBERSARTAN/HYDROCHLOROTHIAZIDE ZENTIVA
Brand Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS IFIRMACOMBI (AUTHORIZED: HYPERTENSION)
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
WHO-ATC C09DA04
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
EMA ASSESSMENT REPORTS SARBEVEL (AUTHORIZED: HYPERTENSION)
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
EMA ASSESSMENT REPORTS IRBESARTAN HYDROCHLOROTHIAZIDE ZENTIVA (AUTHORIZED: HYPERTENSION)
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
WHO-ATC C09DB05
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
EMA ASSESSMENT REPORTS KARVEA (AUTHORIZED: HYPERTENSION)
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
FDA ORPHAN DRUG 496715
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
EMA ASSESSMENT REPORTS IRBESARTAN TEVA (AUTHORIZED: HYPERTENSION)
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
EMA ASSESSMENT REPORTS IRBESARTAN ZENTIVA (AUTHORIZED: HYPERTENSION)
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
EMA ASSESSMENT REPORTS COAPROVEL (AUTHORIZED: HYPERTENSION)
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
NCI_THESAURUS C66930
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
NDF-RT N0000175561
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
NDF-RT N0000000070
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
EMA ASSESSMENT REPORTS IRBESARTAN BMS (WITHDRAWN: HYPERTENSION)
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
EMA ASSESSMENT REPORTS IRBESARTAN HYDROCHLOROTHIAZIDE BMS (WITHDRAWN: HYPERTENSION)
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
EMA ASSESSMENT REPORTS KARVEZIDE (AUTHORIZED: HYPERTENSION)
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
WHO-VATC QC09DB05
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
WHO-VATC QC09CA04
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
WHO-ATC C09CA04
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
WHO-VATC QC09DA04
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
EMA ASSESSMENT REPORTS IRBESARTAN HYDROCHLOROTHIAZIDE TEVA (AUTHORIZED: HYPERTENSION)
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
LIVERTOX 515
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
Code System Code Type Description
FDA UNII
J0E2756Z7N
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY
DRUG BANK
DB01029
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY
WIKIPEDIA
IRBESARTAN
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY
IUPHAR
589
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY
EPA CompTox
138402-11-6
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY
MERCK INDEX
M6397
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY Merck Index
PUBCHEM
3749
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY
RXCUI
83818
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY RxNorm
LACTMED
Irbesartan
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY
ChEMBL
CHEMBL1513
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY
HSDB
8215
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY
USP_CATALOG
1347700
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY USP-RS
MESH
C081309
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY
INN
7229
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY
CAS
138402-11-6
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY
EVMPD
SUB08293MIG
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY
DRUG CENTRAL
1481
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY
NCI_THESAURUS
C29130
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY